NCT04874844 2021-05-10JY025 is a First-line Treatment for EGFR Mutated NSCLC Phase II and III Clinical Trials of Efficacy and SafetyBeijing Dongfang Biotech Co., Ltd.Phase 2/3 Unknown420 enrolled